Advertisement

Archives of Toxicology

, Volume 93, Issue 10, pp 2787–2796 | Cite as

Aluminium in plasma and tissues after intramuscular injection of adjuvanted human vaccines in rats

  • Karin WeisserEmail author
  • Thomas Göen
  • Jennifer D. Oduro
  • Gaby Wangorsch
  • Kay-Martin O. Hanschmann
  • Brigitte Keller-Stanislawski
Inorganic Compounds
  • 112 Downloads

Abstract

Aluminium (Al) toxicokinetics after intramuscular (IM) injection of Al-adjuvanted vaccines is unknown. Since animal data are required for modeling and extrapolation, a rat study was conducted measuring Al in plasma and tissues after IM injection of either plain Al-hydroxide (pAH) or Al-phosphate (pAP) adjuvant (Al dose 1.25 mg), single human doses of three Al-adjuvanted vaccines (V1, V2, and V3; Al doses 0.5–0.82 mg), or vehicle (saline). A significant increase in Al plasma levels compared to controls was observed after pAP (AUC(0–80 d), mean ± SD: 2424 ± 496 vs. 1744 ± 508 µg/L*d). Percentage of Al dose released from injected muscle until day 80 was higher after pAP (66.9%) and AP-adjuvanted V3 (85.5%) than after pAH and AH-adjuvanted V1 (0 and 22.3%, resp.). Estimated absolute Al release was highest for pAP (836.8 µg per rat). Al concentration in humerus bone was increased in all groups, again strongest in the pAP group [3.35 ± 0.39 vs. 0.05 ± 0.06 µg/g wet weight (ww)]. Extrapolated amounts in whole skeleton corresponded to 5–12% of the released Al dose. Very low brain Al concentrations were observed in all groups (adjuvant group means 0.14–0.29 µg/g ww; control 0.13 ± 0.04 µg/g ww). The results demonstrate systemically available Al from marketed vaccines in rats being mainly detectable in bone. Al release appears to be faster from AP- than AH-adjuvants. Dose scaling to human adults suggests that increase of Al in plasma and tissues after single vaccinations will be indistinguishable from baseline levels.

Keywords

Aluminium Adjuvants Systemic availability Rats Intramuscular Vaccine 

Notes

Acknowledgements

The authors thank Barbara Verhoeven for her technical assistance and Daniela Golomb for preparation of the treatment formulations.

Funding

The project was funded by the German Ministry of Health (ZMVI1-2515-FSB-772).

Compliance with ethical standards

Conflict of interest

Author Jennifer D. Oduro declares that she is employee at preclinics GmbH, a contract research organization that has received payment for conducting the animal study. All other authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution (preclinics GmbH, Germany) at which the studies were conducted.

References

  1. Bagi CM, Berryman E, Moalli MR (2011) Comparative bone anatomy of commonly used laboratory animals: implications for drug discovery. Comp Med 61:76–85PubMedPubMedCentralGoogle Scholar
  2. Barak MM, Lieberman DE, Hublin JJ (2013) Of mice, rats and men: trabecular bone architecture in mammals scales to body mass with negative allometry. J Struct Biol 183:123–131CrossRefGoogle Scholar
  3. Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B (2012) Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92:40–49CrossRefGoogle Scholar
  4. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484CrossRefGoogle Scholar
  5. Crépeaux G, Eidi H, David MO, Tzavara E, Giros B, Exley C, Curmi PA, Shaw CA, Gherardi RK, Cadusseau J (2015) Highly delayed systemic translocation of aluminum-based adjuvant in CD1 mice following intramuscular injections. J Inorg Biochem 152:199–205CrossRefGoogle Scholar
  6. FDA/CDER guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers (2005) https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf. Accessed 13 Sept 2019
  7. Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA (1997) In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 15:1314–1318CrossRefGoogle Scholar
  8. Gherardi RK, Eidi H, Crépeaux G, Authier FJ, Cadusseau J (2015) Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol 6:4CrossRefGoogle Scholar
  9. He P, Zou Y, Hu Z (2015) Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother 11:477–488CrossRefGoogle Scholar
  10. Hellström HO, Mjöberg B, Mallmin H, Michaëlsson K (2005) The aluminum content of bone increases with age, but is not higher in hip fracture cases with and without dementia compared to controls. Osteoporos Int 16:1982–1988CrossRefGoogle Scholar
  11. Hellström HO, Mjöberg B, Mallmin H, Michaëlsson K (2006) No association between the aluminium content of trabecular bone and bone density, mass or size of the proximal femur in elderly men and women. BMC Musculoskelet Disord 7:69CrossRefGoogle Scholar
  12. Hem SL, HogenEsch H (2007) Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 6:685–698CrossRefGoogle Scholar
  13. Hirayama M, Iijima S, Iwashita M, Akiyama S, Takaku Y, Yamazaki M, Omori T, Yumoto S, Shimamura T (2011) Aging effects of major and trace elements in rat bones and their mutual correlations. J Trace Elem Med Biol 25:73–84CrossRefGoogle Scholar
  14. HogenEsch H, O’Hagan DT, Fox CB (2018) Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3:51CrossRefGoogle Scholar
  15. HogenEsch H (2013) Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 3:406CrossRefGoogle Scholar
  16. House E, Esiri M, Forster G, Ince PG, Exley C (2012) Aluminium, iron and copper in human brain tissues donated to the Medical research council’s cognitive function and ageing study. Metallomics 4:56–65CrossRefGoogle Scholar
  17. Immunization Safety Review (2001) Thimerosal-containing vaccines and neurodevelopmental disorders. Institute of Medicine (US) Immunization safety Review Committee. National Academies Press (US), WashingtonGoogle Scholar
  18. Immunization Safety Review (2004) Vaccines and Autism. Institute of Medicine (US) Immunization safety review committee. Washington (DC): National Academies Press (US)Google Scholar
  19. Klein GL (2019) Aluminum toxicity to bone: A multisystem effect? Osteoporos Sarcopenia 5:2–5CrossRefGoogle Scholar
  20. Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J et al (2007) Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev 10(Suppl 1):1–269CrossRefGoogle Scholar
  21. Lin WT, Chen RC, Lu WW, Liu SH, Yang FY (2015) Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer’s disease rat model. Sci Rep 5:9671CrossRefGoogle Scholar
  22. Lu H, Rosenbaum S (2014) Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther 19:262–276PubMedPubMedCentralGoogle Scholar
  23. Masson JD, Crépeaux G, Authier FJ, Exley C, Gherardi RK (2018) Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants. J Inorg Biochem 181:87–95CrossRefGoogle Scholar
  24. Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27–31CrossRefGoogle Scholar
  25. Netterlid E, Hindsén M, Siemund I, Björk J, Werner S, Jacobsson H, Güner N, Bruze M (2013) Does allergen-specific immunotherapy induce contact allergy to aluminium? Acta Derm Venereol 93:50–56CrossRefGoogle Scholar
  26. O’Flaherty EJ (1991) Physiologically based models for bone-seeking elements. I. Rat skeletal and bone growth. Toxicol Appl Pharmacol 111:299–312CrossRefGoogle Scholar
  27. Ogasawara Y, Sakamoto T, Ishii K, Takahashi H, Tanabe S (2002) Effects of the administration routes and chemical forms of aluminum on aluminum accumulation in rat brain. Biol Trace Elem Res 86:269–278CrossRefGoogle Scholar
  28. Ph. Eur. 9.6, Monograph 0153: Vaccines for human use (07/2018)Google Scholar
  29. Powell BS, Andrianov AK, Fusco PC (2015) Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res 4:23–45CrossRefGoogle Scholar
  30. Priest ND (2004) The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit 6:375–403CrossRefGoogle Scholar
  31. Seeber SJ, White JL, Hem SL (1991) Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J Parenter Sci Technol 45:156–159PubMedGoogle Scholar
  32. Shardlow E, Mold M, Exley C (2018) Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action. Allergy Asthma Clin Immunol 14:80.  https://doi.org/10.1186/s13223-018-0305-2 CrossRefPubMedPubMedCentralGoogle Scholar
  33. Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–921CrossRefGoogle Scholar
  34. Steinhausen C (1997) Untersuchung der Aluminiumbiokinetik mit 26Al und Beschleunigermassenspektrometrie. Dissertation, Technical University of Munich, GermanyGoogle Scholar
  35. Sun X, Liu J, Zhuang C, Yang X, Han Y, Shao B et al (2016) Aluminum trichloride induces bone impairment through TGF-β1/Smad signaling pathway. Toxicology 371:49–57CrossRefGoogle Scholar
  36. Sun X, Cao Z, Zhang Q, Liu S, Xu F, Che J et al (2015) Aluminum trichloride impairs bone and downregulates Wnt/β-catenin signaling pathway in young growing rats. Food Chem Toxicol 86:154–162CrossRefGoogle Scholar
  37. Valtulini S, Macchi C, Ballanti P, Cherel Y, Laval A, Theaker JM, Bak M, Ferretti E, Morvan H (2005) Aluminium hydroxide-induced granulomas in pigs. Vaccine 23:3999–4004CrossRefGoogle Scholar
  38. Van Landeghem GF, D’Haese PC, Lamberts LV, Djukanovic L, Pejanovic S, Goodman WG et al (1998) Low serum aluminum values in dialysis patients with increased bone aluminum levels. Clin Nephrol 50:69–76PubMedGoogle Scholar
  39. Veiga M, Bohrer D, Banderó CR, Oliveira SM, do Nascimento PC, Mattiazzi P et al (2013) Accumulation, elimination, and effects of parenteral exposure to aluminum in newborn and adult rats. J Inorg Biochem 128:215–220CrossRefGoogle Scholar
  40. Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E (2005) Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23:1359–1367CrossRefGoogle Scholar
  41. Walker VR, Sutton RA, Meirav O, Sossi V, Johnson R, Klein J et al (1994) Tissue disposition of 26aluminium in rats measured by accelerator mass spectrometry. Clin Invest Med 17:420–425PubMedGoogle Scholar
  42. Weisser K, Göen T, Oduro JD, Wangorsch G, Hanschmann KMO, Keller-Stanislawski B (2019) Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. Arch Toxicol 93:37–47CrossRefGoogle Scholar
  43. Weisser K, Stübler S, Matheis W, Huisinga W (2017) Towards toxicokinetic modelling of aluminium exposure from adjuvants in medicinal products. Regul Toxicol Pharmacol 88:310–321CrossRefGoogle Scholar
  44. WHO Expert Committee on Biological Standardization, sixty-sixth report. Geneva: World Health Organization; 2016 (WHO technical report series; no. 999)Google Scholar
  45. WHO (2012) Global advisory committee for vaccine safety“(GACVS), Report of Meeting Held 6–7 June 2012. WHO Weekly Epidemiological RecordGoogle Scholar
  46. Yokel RA, McNamara PJ (2001) Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol 88:159–167CrossRefGoogle Scholar
  47. Yumoto S, Nagai H, Imamura M, Matsuzaki H, Hayashi K, Masuda A et al (1997) 26Al uptake and accumulation in the rat brain. Nucl Instrum Methods Phys Res B 123:279–282CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines)LangenGermany
  2. 2.Institute and Outpatient Clinic of Occupational, Social and Environmental MedicineFriedrich-Alexander-Universität Erlangen-NürnbergErlangenGermany
  3. 3.Preclinics GmbHPotsdamGermany

Personalised recommendations